Abstracts tagged "Pulmonary Involvement"

Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Masataka Kuwana¹, Yuichiro Shirai¹, Hidekata Yasuoka¹, Tsutomu Takeuchi¹ and Kenichi Masui², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Jessica K. Gordon³, Paula Lauto⁴ and Virginia D. Steen⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
Abstract Number: 2585 • 2013 ACR/ARHP Annual Meeting
Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Sumiaki Tanaka¹, Yoshiyuki Arinuma¹, Tatsuhiko Wada¹, Tatsuo Nagai², Jun Okada³ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Recentry, development of potent effective newer drugs for pulmonary arterial hypertension (PAH) have resulted in improving survival of the patients. However, the prognosis of…
Abstract Number: 2072 • 2013 ACR/ARHP Annual Meeting
Decreased Number Of Circulating NK Cells and Dramatic Lack Of IFN-Gamma Production In Patients With Antisynthetase Syndrome
Baptiste Hervier^1,2, Yves Allenbach^3,4, Fleur Cohen-Aubart⁵, Micheline Pha⁶, Lenaig Mescam-Mancini⁷, David Saadoun⁸, Alexis Mathian^5,6, Olivier Benveniste^9,10 and Vincent Vieillard¹, ¹INSERM UMR-S 1135, UPMC, Paris, France, ²Internal Medicine & Clinical Immunology Dpt, Pitié-Salpêtrière Hospital, APHP, Paris, France, ³Internal Medicine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁴INSERM UMR974, UPMC, Paris, France, ⁵Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁶INSERM UMR-S 945, UPMC, Paris, France, ⁷Pathology Dpt, University hospital, Grenoble, France, ⁸DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁹UMR 974, Sorbonne Universités, University Pierre et Marie-Curie-Paris 6, INSERM, Paris, France, ¹⁰Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France
Background/Purpose: Antisynthetase syndrome (ASS) is a rare autoimmune myositis associated with interstitial lung disease (ILD) and characterized by specific anti-tRNA-synthetase autoantibodies (ARS). To date, the…
Abstract Number: 2052 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis
Carl Orr¹, Cormac McCarthy¹, Johan Meurling¹, Paul G. O'Connell², Cedric Gunaratnam^1,3 and Noel G McElvaney¹, ¹Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland, ²Rheumatology, Beaumont Hospital, Dublin, Ireland, ³Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland
Background/Purpose: Arthritis in cystic fibrosis (CF) can be very incapacitating, and it is mainly of three types: CF arthritis, hypertrophic osteoarthropathy, and arthritis due to…
Abstract Number: 2012 • 2013 ACR/ARHP Annual Meeting
Gender Influences On Organ Manifestations In a New Orleans Sarcoidosis Population
Adam Janot¹, McCall Walker², Mary Yu¹, Harmanjot K. Grewal³, Matthew R. Lammi^4,5 and Lesley Ann Saketkoo^6,7, ¹Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²LSUHSC School of Medicine, New Orleans, LA, ³Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ⁴Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁵Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ⁶LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ⁷Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: Sarcoidosis is a multi-organ disease in which pulmonary manifestations predominate. The skin, eyes, heart, gastrointestinal tract (GI), reticuloendothelial, renal and nervous systems are also…
Abstract Number: 1936 • 2013 ACR/ARHP Annual Meeting
Quality Of Care In Patients At Risk For Pulmonary Involvement: Assessment Of Pulmonary Screening In Systemic Sclerosis and Myositis Patients In a General Rheumatology Clinic
Michael G. Indelicato¹, Janet E. Lewis², Vincent J. Giuliano³ and Donald L. Kimpel⁴, ¹Rheumatology, University of Virginia, Charlottesville, VA, ²Rheumatology, University of Virginia School of Medicine, Charlottesville, VA, ³University of Virginia, Charlottesville, VA, ⁴Rheumatology and Immunology, University of Virginia School of Medicine, Charlottesville, VA
Background/Purpose: As a quality assessment tool to evaluate patient care in a general Rheumatology Clinic, we determined the frequency of screening for pulmonary hypertension and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.